Aqilion focuses on diseases caused by chronic inflammation and dysfunctional immunological reactions
We explore novel scientific findings describing the biology behind the diseases and focus on developing new innovative treatments. Our mission is clear, we identify opportunities based on solid research resting on a firm biological foundation offering both clinical relevance and patient benefit.
Sarah Fredriksson, CEO, presents Aqilion:
Aqilion is a biotech company developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions. The company is active in early phases of drug discovery, from idea stage to early clinical development.
Main focus is to develop and refine Aqilion’s project portfolio within chronic inflammation and immunology.
Press releases
-
January 19, 2022Aqilion strengthens its operational team in preclinical development
-
January 19, 2022Aqilion stärker sitt operationella team inom preklinisk utveckling
-
December 21, 2021Aqilion presents Nomination Committee for the 2022 Annual General Meeting
-
December 21, 2021Aqilion presenterar valberedning inför årsstämman 2022